Compile Data Set for Download or QSAR
Report error Found 781 Enz. Inhib. hit(s) with Target = 'Ubiquitin carboxyl-terminal hydrolase 2'
TargetUbiquitin carboxyl-terminal hydrolase 2(Human)
Jagiellonian University

Curated by ChEMBL
LigandPNGBDBM50458416(CHEMBL1230155)
Affinity DataKd:  9.00E+5nMAssay Description:Binding affinity to 15N-Gly/Cys/Ser/Trp-labeled human USP2a expressed in Escherichia coli BL21(DE3) assessed as change in chemical shift by NMR metho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details Article
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 2(Human)
Jagiellonian University

Curated by ChEMBL
LigandPNGBDBM442822(PR-619)
Affinity DataEC50:  7.20E+3nMAssay Description:Inhibition of USP2 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2024
Entry Details
PubMed
LigandPNGBDBM50612971(CHEMBL5273043)
Affinity DataKd:  7.90nMAssay Description:Binding affinity to recombinant human N-terminal His6-tagged USP21 (209 to 563 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissoci...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612988(CHEMBL5286335)
Affinity DataKd:  5.80nMAssay Description:Binding affinity to recombinant human N-terminal His6-tagged USP21 (209 to 563 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissoci...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612991(CHEMBL5279102)
Affinity DataKd:  2.20nMAssay Description:Binding affinity to recombinant human N-terminal His6-tagged USP21 (209 to 563 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissoci...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612991(CHEMBL5279102)
Affinity DataEC50:  0.0950nMAssay Description:Binding affinity to C-terminally NanoLuc HiBiT-tagged USP21 transfected in human HEK293T cells ssessed as thermal stability at 49 degreeC incubated f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612992(CHEMBL5285026)
Affinity DataEC50: >1.00E+5nMAssay Description:Binding affinity to C-terminally NanoLuc HiBiT-tagged USP21 transfected in human HEK293T cells ssessed as thermal stability at 49 degreeC incubated f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612991(CHEMBL5279102)
Affinity DataEC50:  0.0166nMAssay Description:Inhibition of full-length human USP21 transfected in human HEK293T cells co-transfected with NF-kappaB reporter firefly luciferase plasmid assessed a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50652792(CHEMBL3752910)
Affinity DataKd:  3.17E+4nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708839(US20240425513, Example 20)
Affinity DataIC50: 1nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

LigandPNGBDBM50612991(CHEMBL5279102)
Affinity DataIC50: 2nMAssay Description:Inhibition of human USP21 using ubiquitin rhodamine 110 110 as substrate preincubated for 15 to 20 mins followed by enzyme addition and measured afte...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612991(CHEMBL5279102)
Affinity DataIC50: 6nMAssay Description:Inhibition of human full length USP21 using Btn-Ahx-PNIRFLD-K(Ubi)-LPQQT-GD-amide as substrate preincubated for 15 to 20 mins followed by substrate a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612990(CHEMBL5268828)
Affinity DataIC50: 8nMAssay Description:Inhibition of human USP21 using ubiquitin rhodamine 110 110 as substrate preincubated for 15 to 20 mins followed by enzyme addition and measured afte...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612988(CHEMBL5286335)
Affinity DataIC50: 11nMAssay Description:Inhibition of human USP21 using ubiquitin rhodamine 110 110 as substrate preincubated for 15 to 20 mins followed by enzyme addition and measured afte...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612990(CHEMBL5268828)
Affinity DataIC50: 12nMAssay Description:Inhibition of human full length USP21 using Btn-Ahx-PNIRFLD-K(Ubi)-LPQQT-GD-amide as substrate preincubated for 15 to 20 mins followed by substrate a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612988(CHEMBL5286335)
Affinity DataIC50: 18nMAssay Description:Inhibition of human full length USP21 using Btn-Ahx-PNIRFLD-K(Ubi)-LPQQT-GD-amide as substrate preincubated for 15 to 20 mins followed by substrate a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612984(CHEMBL5277351)
Affinity DataIC50: 28nMAssay Description:Inhibition of human USP21 using ubiquitin rhodamine 110 110 as substrate preincubated for 15 to 20 mins followed by enzyme addition and measured afte...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612984(CHEMBL5277351)
Affinity DataIC50: 32nMAssay Description:Inhibition of human full length USP21 using Btn-Ahx-PNIRFLD-K(Ubi)-LPQQT-GD-amide as substrate preincubated for 15 to 20 mins followed by substrate a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612981(CHEMBL5275560)
Affinity DataIC50: 32nMAssay Description:Inhibition of human USP21 using ubiquitin rhodamine 110 110 as substrate preincubated for 15 to 20 mins followed by enzyme addition and measured afte...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612986(CHEMBL5267932)
Affinity DataIC50: 32nMAssay Description:Inhibition of human USP21 using ubiquitin rhodamine 110 110 as substrate preincubated for 15 to 20 mins followed by enzyme addition and measured afte...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612987(CHEMBL5271965)
Affinity DataIC50: 36nMAssay Description:Inhibition of human USP21 using ubiquitin rhodamine 110 110 as substrate preincubated for 15 to 20 mins followed by enzyme addition and measured afte...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM50618514(CHEMBL5401467)
Affinity DataIC50: 40nMAssay Description:Inhibition of USP28 (149 to 703 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) using Ub-AMC as substrate by fluorescence based a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2024
Entry Details
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM50618514(CHEMBL5401467)
Affinity DataIC50: 40nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
LigandPNGBDBM50612987(CHEMBL5271965)
Affinity DataIC50: 45nMAssay Description:Inhibition of human full length USP21 using Btn-Ahx-PNIRFLD-K(Ubi)-LPQQT-GD-amide as substrate preincubated for 15 to 20 mins followed by substrate a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612989(CHEMBL5266176)
Affinity DataIC50: 45nMAssay Description:Inhibition of human USP21 using ubiquitin rhodamine 110 110 as substrate preincubated for 15 to 20 mins followed by enzyme addition and measured afte...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708840(US20240425513, Example 21)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708841(US20240425513, Example 22)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708843(US20240425513, Example 24)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708844(US20240425513, Example 25)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708845(US20240425513, Example 26)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708846(US20240425513, Example 27)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708847(US20240425513, Example 28)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708848(US20240425513, Example 29)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708851(US20240425513, Example 32)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708852(US20240425513, Example 33)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708853(US20240425513, Example 34)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708854(US20240425513, Example 35)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708855(US20240425513, Example 36)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708856(US20240425513, Example 37)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708857(US20240425513, Example 38)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708858(US20240425513, Example 39)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708859(US20240425513, Example 40)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708860(US20240425513, Example 41)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708862(US20240425513, Example 43)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708863(US20240425513, Example 44)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

LigandPNGBDBM50612983(CHEMBL5279700)
Affinity DataIC50: 65nMAssay Description:Inhibition of human full length USP21 using Btn-Ahx-PNIRFLD-K(Ubi)-LPQQT-GD-amide as substrate preincubated for 15 to 20 mins followed by substrate a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612982(CHEMBL5280287)
Affinity DataIC50: 72nMAssay Description:Inhibition of human full length USP21 using Btn-Ahx-PNIRFLD-K(Ubi)-LPQQT-GD-amide as substrate preincubated for 15 to 20 mins followed by substrate a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612979(CHEMBL5274527)
Affinity DataIC50: 72nMAssay Description:Inhibition of human USP21 using ubiquitin rhodamine 110 110 as substrate preincubated for 15 to 20 mins followed by enzyme addition and measured afte...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612981(CHEMBL5275560)
Affinity DataIC50: 73nMAssay Description:Inhibition of human full length USP21 using Btn-Ahx-PNIRFLD-K(Ubi)-LPQQT-GD-amide as substrate preincubated for 15 to 20 mins followed by substrate a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
LigandPNGBDBM50612980(CHEMBL5275910)
Affinity DataIC50: 74nMAssay Description:Inhibition of human full length USP21 using Btn-Ahx-PNIRFLD-K(Ubi)-LPQQT-GD-amide as substrate preincubated for 15 to 20 mins followed by substrate a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
Displayed 1 to 50 (of 781 total ) | Next | Last >>
Jump to: